At the Medicap Pharmacy® stores, we are dedicated to providing products and services to care for your family’s wellness. One of those services is health news you can trust. Use the filters to focus on the information that is important to you, then bookmark this page to make it a regular stop anytime you’re online.
Enbrel Biosimilar Gets Green Light
Enbrel's new biosimilar recently got the green light it needed to treat several inflammatory health conditions.
Inflammatory Disease Rx Gets Green Light
The US Food and Drug Administration (FDA) has approved a new medication to treat multiple chronic inflammatory diseases.
Another Biosimilar Gets a Green Light
The US Food and Drug Administration (FDA) has approved another biosimilar. This one is meant to treat multiple conditions that affect the immune system.
Green Light for Biosimilar to Humira
The US Food and Drug Administration has approved its fourth biosimilar.
FDA Approves First Biosimilar Etanercept
The US Food and Drug Administration (FDA) has approved the first biosimilar etanercept.
Are 'Generic' Biologics the Same as the 'Brand'?
Generic versions of often expensive brand-name biologic medications appear safe and effective on the whole, a new study found.
Second Biosimilar Gets FDA Nod
The US Food and Drug Administration (FDA) has approved the second-ever biosimilar, and it's meant to treat multiple conditions that affect the immune system.
Could Antibiotics Be Tied to Arthritis in Kids?
Antibiotics are miracle drugs that have saved millions of lives, but some worry that their overuse could have serious consequences. Now there may be yet another cause for concern.
Eli Lilly Announces Phase 3 Trial Results of Arthritis Drug
INDIANAPOLIS, Feb. 23, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announce that the investigational medicine baricitinib demonstrated a statistically significant improvement compared to placebo in a second consecutive Phase 3 trial in rheumatoid arthritis (RA).
Psoriatic Arthritis Rx Performed Well in Phase 2 Trial
Amgen (NASDAQ:AMGN) and AstraZeneca today announced that results from a Phase 2 study evaluating brodalumab in 168 patients with psoriatic arthritis were published in The New England Journal of Medicine (NEJM).